Company Overview
Entera Bio Ltd. operates as a clinical stage biotechnology company dedicated to developing oral peptide and protein replacement therapies aimed at addressing significant unmet medical needs within the healthcare sector. By leveraging its proprietary N-Tab platform, the firm seeks to simultaneously stabilize peptides within the gastrointestinal tract while promoting their absorption into the bloodstream, a technological approach designed to overcome traditional delivery limitations. The company maintains a small operational footprint with a workforce of 20 employees, reflecting a lean organizational structure typical of early-stage biotech ventures. Its current market capitalization stands at $51.82M, while reported annual revenue for the trailing twelve months totals $124,000, indicating that the company is in an investment phase where capital allocation toward research and development outweighs commercial revenue generation. These valuation and revenue figures underscore Entera Bio's position as a pre-revenue or early-revenue entity, where the primary focus remains on advancing its clinical pipeline rather than achieving profitability or market dominance in the immediate term.
Financial Health
The company reported a trailing twelve-month revenue of $124,000, yet this minimal income is offset by a net income loss of $-10,781,000 and an EBITDA of $-10,790,000. The substantial gap between the negligible revenue and the multi-million dollar net losses reveals a cost structure heavily dominated by research, development, and clinical trial expenses rather than cost of goods sold. Free cash flow for the period was $-11,764,000, which signifies that the company is burning cash at a rapid pace, limiting its financial flexibility and necessitating a reliance on external financing or existing cash reserves to sustain operations. Margins across the board reflect this aggressive burn rate; the gross margin is 0.0%, the operating margin is -8729.0%, and the profit margin is 0.0%, all figures that indicate the company has not yet reached the economies of scale required to generate profit on sales. On the balance sheet, the company holds $8.57M in cash against $211,000 in debt, resulting in a debt-to-equity ratio of 1.39, which suggests a capital structure where equity claims exceed debt obligations despite the high leverage ratio. The current ratio is 10.83, a metric that indicates strong short-term liquidity, meaning the company possesses ample current assets to cover its short-term liabilities even while burning cash. Return on Equity stands at -99.4% and Return on Assets is -53.8%, metrics that reveal management is currently unable to generate positive returns on the capital invested or assets held, a common characteristic of clinical-stage firms focused on future product potential rather than current profitability.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -2.05, a figure that implies negative earnings expectations for the upcoming period and suggests the market is pricing in continued losses or a turnaround scenario. The price-to-book ratio is 3.38, indicating that the market values the company at a premium of over three times its tangible book value, a multiple often seen in biotechnology firms where intellectual property and pipeline potential are valued above current asset holdings. Alternative valuation metrics such as the price-to-sales ratio of 417.89 and an EV/EBITDA of -4.03 further highlight the disconnect between current revenue generation and market valuation, suggesting the stock price is driven entirely by speculative growth expectations rather than cash flow or earnings power. The 52-week trading range spans from a low of $1.00 to a high of $3.22, placing the current valuation context within this historical volatility band and reflecting the high-risk nature of the asset. The stock exhibits a beta of 1.48, which means its price volatility is significantly higher than the broader market, moving with greater intensity than the S&P 500 and reflecting the heightened sensitivity of biotech stocks to clinical trial results and regulatory news.
Growth & Income
The reported revenue growth year-over-year is N/A and earnings growth year-over-year is also N/A, indicating that the company has either recently commenced operations or lacks sufficient historical data to calculate meaningful growth rates. Since the company has not generated profitable earnings, the concept of a dividend yield is N/A, and the payout ratio is 0.0%, which confirms that Entera Bio reinvests all available resources and any potential earnings back into its R&D pipeline rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage companies that prioritize advancing their N-Tab platform and conducting clinical trials over providing immediate income returns. The overall growth and income profile is characterized by zero current income generation, negative historical growth metrics, and a complete absence of dividend payments, painting a picture of a pure growth play that relies entirely on future clinical successes to unlock value.